cas 6148-64-7|| where to buy Potassium 3-ethoxy-3-oxopropanoate

Название продукции:Potassium 3-ethoxy-3-oxopropanoate

IUPAC Name:potassium 3-ethoxy-3-oxopropanoate

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM254041-1000g	in stock	Ʊƻ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6148-64-7 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:6148-64-7; Молекулярная формула:C5H7KO4; Точка плавления:-; Smiles-код:O=C([O-])CC(OCC)=O.[K+]; Плотность:

: Номер в каталоге:CM254041; Молекулярная масса:170.21; Точка кипения:297.3°C at 760 mmHg; Номер Mdl:MFCD00035603; Хранение:Keep in a tight container and store at ambient temperature

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: BNC-210; Bionomics Ltd.’s drug candidate, BNC-210 would be advanced into Phase 3 studies in Social Anxiety Disorder (SAD) after the successful End-of-Phase 2 Meeting with the U.S. FDA in September. BNC-210 has a unique action potential that depends on acetylcholine neurotransmission and allosteric modulation of α7 nAChR. It is designed to treat patients with serious central nervous system (CNS) disorders with limited side effects. BNC-210 received Fast-Track designation from the FDA for the acute treatment of SAD.

: KB-0742; Kronos Bio announces the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer (HGSOC). Many cancers exhibit transcriptional deregulation, often characterized by gene amplifications of MYC family oncogene. Targeting the transcription elongation cofactor, cyclin-dependent kinase 9 (CDK9) has emerged as a therapeutic strategy to disrupt MYC oncogenic activity.
KB-0742 is an oral highly selective CDK9 inhibitor designed for the treatment of patients with MYC-amplified and other transcriptionally addicted relapsed or refractory solid tumors, including ovarian, lung, and triple-negative breast cancers.